Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates

  • Companies to seek antibody-drug conjugates (ADCs) to treat cancers with unmet needs
  • Collaboration to use ImmunoGen’s ADC payload technology directed to targets identified by OBT
  • Each company can select a number of preclinical programs for internal development
  • OBT will receive an upfront payment, and each company is eligible to receive milestone payments plus tiered royalties

OXFORD, England and SAN JOSECal., June 13, 2022 /PRNewswire/ — Oxford BioTherapeutics (OBT), a clinical-stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, today announced a collaboration to research, develop and commercialize new, first-in-class ADCs with ImmunoGen (IMGN), a leader in the expanding field of ADCs for the treatment of cancer. The companies will use ImmunoGen’s binding payload technology directed to novel targets identified through OBT’s proprietary OGAP® discovery platform. The companies will support these R&D efforts through joint funding and by combining their respective proprietary technologies.

“I am very excited about our new partnership with ImmunoGen, a leader in ADC development,” said Christian RoehlffPhD, CEO of Oxford BioTherapeutics. “The company’s expertise, combined with the unique targets of our OGAP® database, offers the potential to bolster our respective drug pipelines with novel and highly differentiated ADCs for cancer patients in need of new therapeutic options. »

As part of the agreement, OBT will receive an upfront payment from ImmunoGen, reflecting OBT’s preclinical programs to be included in the partnership.

Additionally, once the antibodies generated by OBT have been coupled with ImmunoGen’s proprietary binding payload technology, each company will have the ability to select one or more development programs to develop on their own.

Each company is eligible to receive milestone payments based on the achievement of predefined development, regulatory and commercial milestones, as well as tiered royalties as a percentage of worldwide commercial sales, with respect to each program selected by the other society. Once a company has chosen a given program, it will be solely responsible for all R&D costs associated with the specific program.

“OBT has demonstrated expertise in identifying novel targets for the development of specific antibodies – two key elements for generating successful ADCs,” said Stacy CoenSenior Vice President and Chief Commercial Officer of ImmunoGen. “This expertise, combined with ImmunoGen’s portfolio of cancer payloads and linkers, will be instrumental as both companies strive to develop novel ADCs designed to address cancers with high unmet need.” We look forward to working with OBT as we expand and diversify our investments. in ADC’s research capabilities, deepen our pipeline and transition to a fully integrated oncology company. »

ImmunoGen’s portfolio includes next-generation maytansinoids, DNA-acting toxins, novel camptothecin toxins and proprietary linkers. This collaboration will use novel targets identified by OBT combined with ImmunoGen’s proprietary toxins and associated linkers. OBT has clinical experience with ImmunoGen’s ADC platform and DM4 payload, which is used in the lead program of OBT OBT076, an ADC currently in clinical trials as monotherapy, as well as in combination with checkpoint inhibitors, in patients with advanced or refractory solid tumors, including stomach, bladder, ovarian and lung cancer.

About Oxford BioTherapeutics

Oxford BioTherapeutics is a clinical-stage oncology company based in Oxford, United Kingdom; San Jose, California and Morristown, New Jersey, UNITED STATES; with a pipeline of best-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies designed to address key unmet patient needs for cancer therapy.

OBT’s lead clinical program, OBT076, an ADC using an immunogenic toxin, initiated a clinical trial expansion in the United States in 2021 in patients with advanced or refractory solid tumors, including prostate cancer. stomach, bladder, ovary and lung, where CD205 is overexpressed. Infiltration of tumors by immunosuppressive cells is correlated with adverse effects (less progression-free survival and overall survival), suggesting that this process contributes to the progression of several cancers.

OBT’s proprietary OGAP® Target Discovery Platform is based on one of the world’s largest proprietary cancer membrane proteomics databases, with data on over 5,000 cancer cell proteins providing unique and highly qualified, including three programs in clinical development in the UNITED STATES and Europe. OBT’s IO discovery process provides unique insights into cancer immune cell synapse and has identified several novel monoclonal and bispecific IO antibody candidates for cancer therapies.

OBT’s pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim and cell therapy research collaborations with Kite Pharma as well as other world leaders in antibody development ( such as Amgen, Immunogen, WuXi, Medarex (BMS), Alere (Abbott)). OBT has a strong oncology-focused management team and board of directors with significant experience in the development of IO and antibody-based therapies.

For more information about Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com

For more information, please contact:


OBT investors:
Doctor Christian RoehlffCEO
[email protected]

OBT media:

MEDISTRAV Consulting
Sylvie Berrebi, David Dible, Eleanor PerkinGeorge Underwood
E : [email protected]
T: +44 (0) 203 928 6900

SOURCEOxford BioTherapeutics

Irene B. Bowles